Systematic review / meta-analysis / 2021
Resveratrol supplementation significantly lowered HOMA-IR in type 2 diabetes patients, without significant effects on total cholesterol or triglycerides.
A systematic review and meta-analysis evaluated 15 RCTs involving 896 patients with type 2 diabetes to assess the efficacy and safety of resveratrol supplements. Compared with controls, HOMA-IR was significantly lower in the resveratrol group (WMD: -0.99; 95% CI -1.61, -0.38; P=0.002). No statistically significant differences were observed for total cholesterol (WMD: -7.11; 95% CI -16.28, 2.06; P=0.13), triglycerides (WMD: -2.15; 95% CI -5.52, 1.22; P=0.21), or adverse events (WMD: 2; 95% CI 0.44, 9.03; P=0.37).
- Study type
- Systematic review and meta-analysis of randomized controlled trials
- Who was studied
- 896 patients with type 2 diabetes across 15 RCTs
- What was measured
- Insulin-resistance-related indicators, blood lipids (TC, TG), and adverse events
THE PAPER
Efficacy and Safety of Resveratrol Supplements on Blood Lipid and Blood Glucose Control in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Zhang T, He Q, Liu Y, Chen Z, Hu H. Evid Based Complement Alternat Med, 2021.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.